Hannah E. Stumpf

Hannah E. Stumpf

Auto-generated profile, based on publicly available information

Hannah E. Stumpf

Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
JTJennifer L. Tomlinson
Jennifer L. Tomlinson
BLBinbin Li
Binbin Li
JYJingchun Yang
Jingchun Yang
ELEmilien Loeuillard
Emilien Loeuillard
HSHannah E. Stumpf
Hannah E. Stumpf
SISumera I. Ilyas
Sumera I. Ilyas

12 January 2026 in Hepatology
Verified
Journal Article
Closed access
YDYawen Dong
Yawen Dong
HSHannah E. Stumpf
Hannah E. Stumpf
RSRory L. Smoot
Rory L. Smoot
PSPatrick Starlinger
Patrick Starlinger
MYMark Yarchoan
Mark Yarchoan
SISumera I. Ilyas
Sumera I. Ilyas
Cholangiocarcinoma (CCA) represents a biologically and clinically heterogeneous group of biliary tract malignancies. Growing evidence underscores that the 3 major anatomic subtypes—intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA)—are distinct tumor entities rather than a single disease. Each subtype differs in embryologic origin, carcinogenesis mechanisms, molecular landscape, and immunogenic profile, all of which contribute to variability in diagnosis, treatment responsiveness, and prognosis. The importance of understanding these distinctions is reinforced by the rising global incidence of CCA, which highlights the need for precision medicine approaches based on these subtypes. Recent advances have deepened our insight into subtype-specific risk factors, including chronic biliary diseases and metabolic conditions, while artificial intelligence–driven tools are improving diagnostic accuracy and risk stratification. Surgical innovations now allow for more tailored resections and perioperative care, and therapeutic strategies are increasingly guided by molecular and immune profiling. Emerging strategies for early diagnosis and chemoprevention in high-risk populations further emphasize the significance of recognizing the unique biology of each subtype. In this review, we provide a comprehensive overview of the distinct anatomic subsets of CCA, integrating their molecular and biological foundations with clinical management to inform practice and guide future research.

25 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ELEmilien Loeuillard
Emilien Loeuillard
BLBinbin Li
Binbin Li
HSHannah E. Stumpf
Hannah E. Stumpf
JYJingchun Yang
Jingchun Yang
JWJessica Willhite
Jessica Willhite
SISumera I. Ilyas
Sumera I. Ilyas
Proapoptotic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling as a cause of cancer cell death is a well-established mechanism. However, TRAIL-receptor (TRAIL-R) agonists have had very limited anticancer activity in humans, challenging the concept of TRAIL as a potent anticancer agent. Herein, we demonstrate that TRAIL + cancer cells can leverage noncanonical TRAIL signaling in myeloid-derived suppressor cells (MDSCs) promoting their abundance in murine cholangiocarcinoma (CCA). In multiple immunocompetent syngeneic, orthotopic murine models of CCA, implantation of TRAIL + murine cancer cells into Trail-r -/- mice resulted in a significant reduction in tumor volumes compared to wild type mice. Tumor bearing Trail-r -/- mice had a significant decrease in the abundance of MDSCs due to attenuation of MDSC proliferation. Noncanonical TRAIL signaling with consequent NF-κB activation in MDSCs facilitated enhanced MDSC proliferation. Single cell RNA sequencing and cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq) of CD45 + cells in murine tumors from three distinct immunocompetent CCA models demonstrated a significant enrichment of an NF-κB activation signature in MDSCs. Moreover, MDSCs were resistant to TRAIL-mediated apoptosis due to enhanced expression of cellular FLICE inhibitory protein (cFLIP), an inhibitor of proapoptotic TRAIL signaling. Accordingly, cFLIP knockdown sensitized murine MDSCs to TRAIL-mediated apoptosis. Finally, cancer cell-restricted deletion of Trail significantly reduced MDSC abundance and murine tumor burden. In summary, our findings define a noncanonical TRAIL signal in MDSCs and highlight the therapeutic potential of targeting TRAIL + cancer cells for the treatment of a poorly immunogenic cancer.